Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model

Cancer Biology and Therapy

Volumn 18, Issue 1, 2017, Pages 67-75

  Lee, Dong Hyeon ^a,b   Nam, Joon Yeul ^a   Chang, Young ^a   Cho, Hyeki ^a   Kang, Seong Hee ^a   Cho, Young Youn ^a   Cho, EunJu ^a   Lee, Jeong Hoon ^a   Yu, Su Jong ^a   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

Author keywords

Cancer immunology; hepatocellular carcinoma; immunotherapy

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; RETINOIC ACID; VALPROIC ACID; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; C3H MOUSE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DRUG CYTOTOXICITY; DRUG POTENTIATION; FLUORESCENCE ACTIVATED CELL SORTING; HEPATOCELLULAR CARCINOMA CELL LINE; HUH 7 CELL LINE; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SNU 475 CELL LINE; SNU 761 CELL LINE; SPLEEN CELL; TUMOR VOLUME; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CARCINOMA, HEPATOCELLULAR; DISEASE MODEL; DRUG SCREENING; HUMAN; IMMUNOLOGY; LIVER NEOPLASMS; MALE; PATHOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CYTOKINE-INDUCED KILLER CELLS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C3H; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85012117014     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1276132     Document Type: Article

References (27)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-73.e1; PMID:22537432; http://dx.doi.org/10.1053/j.gastro.2011.12.061
2. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States:where are we? Where do we go? Hepatology 2014; 60:1767-75; PMID:24839253; http://dx.doi.org/10.1002/hep.27222
3. Chen W-T, Chau G-Y, Lui W-Y, Tsay S-H, King K-L, Loong C-C, Wu CW. Recurrent hepatocellular carcinoma after hepatic resection:prognostic factors and long-term outcome. Eur J Surg Oncol (EJSO) 2004; 30:414-20; PMID:15063895; http://dx.doi.org/10.1016/j.ejso.2004.01.013
4. Lee JH, Lee J-H, Lim Y-S, Yeon JE, Song T-J, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148:1383-91. e6; PMID:25747273; http://dx.doi.org/10.1053/j.gastro.2015.02.055
5. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011; 2:363-8; PMID:21716717; http://dx.doi.org/10.7150/jca.2.363
6. Chen Y, Lin J, Guo Z-Q, Lin W-S, Zhou Z-F, Huang C-Z, Chen Q, Ye YB. MHC I-related chain a expression in gastric carcinoma and the efficacy of immunotherapy with cytokine-induced killer cells. Am J Cancer Res 2015; 5:3221; PMID:26693072
7. Blaheta RA, Michaelis M, Driever PH, Cinatl J. Evolving anticancer drug valproic acid:insights into the mechanism and clinical studies. Med Res Rev 2005; 25:383-97; PMID:15637697; http://dx.doi.org/10.1002/med.20027
8. Li J, Bonifati S, Hristov G, Marttila T, Valmary‐Degano S, Stanzel S, Schnölzer M, Mougin C, Aprahamian M, Grekova SP, et al. Synergistic combination of valproic acid and oncolytic parvovirus H‐1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med 2013; 5:1537-55; PMID:24092664; http://dx.doi.org/10.1002/emmm.201302796
9. Li X, Zhu Y, He H, Lou L, Ye W, Chen Y, Wang J. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells. Biochem Biophys Res Commun 2013; 436:259-64; PMID:23726914; http://dx.doi.org/10.1016/j.bbrc.2013.05.088
10. Shirsath N, Rathos M, Chaudhari U, Sivaramakrishnan H, Joshi K. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines. Lung Cancer 2013; 82:214-21; PMID:24051085; http://dx.doi.org/10.1016/j.lungcan.2013.08.010
11. Wu X, Tao Y, Hou J, Meng X, Shi J. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia 2012; 14:1178-89; PMID:23308050; http://dx.doi.org/10.1593/neo.121236
12. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-9; PMID:10426993; http://dx.doi.org/10.1126/science.285.5428.727
13. Kim HM, Lim J, Park S-K, Kang JS, Lee K, Lee CW, Lee KH, Yun MJ, Yang KH, Han G, et al. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 2007; 7:1802-7; PMID:17996691; http://dx.doi.org/10.1016/j.intimp.2007.08.016
14. Rettinger E, KuçI, S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2012; 14:91-103; PMID:21973023; http://dx.doi.org/10.3109/14653249.2011.613931
15. Kim HM, Kang JS, Lim J, Park S-K, Lee K, Yoon YD, Lee CW, Lee KH, Han G, Yang KH, et al. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 2007; 30:1464-70; PMID:18087816; http://dx.doi.org/10.1007/bf02977372
16. Kim YJ, Lim J, Kang JS, Kim HM, Lee HK, Ryu HS, Kim JY, Hong JT, Kim Y, Han SB. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res 2010; 33:1789-95; PMID:21116782; http://dx.doi.org/10.1007/s12272-010-1111-7
17. Tsai C, Leslie JS, Franko-Tobin LG, Prasnal MC, Yang T, Mackey LV, Fuselier JA, Coy DH, Liu M, Yu C, et al. Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II. Arch Gynecol Obstet 2013; 288:393-400; PMID:23435724; http://dx.doi.org/10.1007/s00404-013-2762-7
18. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413:165-71; PMID:11557981; http://dx.doi.org/10.1038/35093109
19. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al. Natural killer cell–mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65:6321-9; PMID:16024634; http://dx.doi.org/10.1158/0008-5472.can-04-4252
20. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734-8; PMID:12384702; http://dx.doi.org/10.1038/nature01112
21. Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, Kwon HS, Park HS, Yeo KS, Lee KU, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 1995; 62:276-82; PMID:7543080
22. Hassan SS, Akram M, King EC, Dockrell HM, Cliff JM. PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PloS One 2015; 10:e0137646; PMID:26359860; http://dx.doi.org/10.1371/journal.pone.0137646
23. Ochoa A, Gromo G, Alter B, Sondel P, Bach F. Long-term growth of lymphokine-activated killer (LAK) cells:role of anti-CD3, beta-IL 1, interferon-gamma and-beta. J Immunol 1987; 138:2728-33; PMID:2435804
24. Anderson PM, Bach FH, Ochoa AC. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Cancer Immunol, Immunother 1988; 27:82-8; PMID:3260824; http://dx.doi.org/10.1007/bf00205763
25. Juengel E, Makarević J, Tsaur I, Bartsch G, Nelson K, Haferkamp A, Blaheta RA. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PloS One 2013; 8:e53100; PMID:23372654; http://dx.doi.org/10.1371/journal.pone.0053100
26. Mackenzie GG, Huang L, Alston N, Ouyang N, Vrankova K, Mattheolabakis G, Constantinides PP, Rigas B. Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PLoS One 2013; 8:e61532; PMID:23650499; http://dx.doi.org/10.1371/journal.pone.0061532
27. Hou H, Lariviere JP, Demidenko E, Gladstone D, Swartz H, Khan N. Repeated tumor pO 2 measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy. Radiother Oncol 2009; 91:126-31; PMID:19013657; http://dx.doi.org/10.1016/j.radonc.2008.10.015